NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets.
A New Board for a New Radiopharma Moment
NAYA Therapeutics, a clinical‑stage biopharmaceutical company, is indeed building therapies around astatine‑211 targeted alpha emitters and NK cell‑engaging bifunctional antibodies, aiming squarely at difficult‑to‑treat cancers. In a sector where capital, credibility, and clinical execution can move as quickly as a PET scan, assembling a seasoned board is less a vanity move and more a prerequisite for serious participation in the radiopharma arms race. The company’s newly announced “world‑class” board is designed to match that ambition, blending deep scientific, clinical, and governance experience to navigate an increasingly competitive radiopharmaceutical landscape. The newly elected Naya board members are:
- Ely Benaim, MD, an accomplished physician-executive with over 25 years of experience in oncology drug development and clinical leadership. A pediatric hematologist/oncologist, he has held senior roles at leading biotechnology and pharmaceutical companies, including Amgen, Millennium/Takeda, Novocure, and SonALAsense. Dr. Benaim currently serves as Chief Medical Officer of Henlius Fosun USA, where he leads U.S. clinical strategy and development initiatives. His career is distinguished by bringing multiple innovative cancer treatments from early clinical trials to FDA approval, improving outcomes for patients worldwide
- Margarita Chavez, JD, a seasoned biopharmaceutical executive with over 25 years of dealmaking experience in the healthcare industry, including in biotech licensing, IPOs, and acquisitions. Margarita currently serves on the boards of Aligos Therapeutics and chairs the Strategy Committee, Newron Pharmaceuticals and chairs the BD Committee, and Xylo Bio as Board Chair. She is also Managing Partner of Ilustrada Group, a biotech advisory. Margarita served as Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics (acquired by Lilly for $3.2Bn), Alector Therapeutics, Jnana Therapeutics (acquired by Otsuka for $1.1Bn), and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott/AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven, Solvay, and the Lupron franchise. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley.
- Anne Lauvergeon, PhD, a leading businesswoman, board member, and political advisor. Anne is the founder and President of ALP (Anne Lauvergeon Partners), an advisory and investment company mostly dedicated to innovation. She has served on over a dozen boards, including American Express, Airbus, Vodafone and TotalEnergies. She was twice named by Time Magazine as one of the 100 most influential people in the world. She previously served as chairman and Chief Executive Officer of global nuclear energy leader AREVA. During her tenure, she initiated the application of nuclear energy to medicine under AREVA Med, which later transformed into radiopharmaceutical leader Orano Med. Some of her previous roles include Partner at Lazard, the world’s largest independent investment bank, President of the French Government’s 2030 Innovation Commission, which oversees €54 billions of planned investment, and Senior Advisor & Deputy Chief-of-Staff to the French President.
- Rahul Singhvi, PhD, MBA, a global leader in the life sciences industry. Rahul was previously cofounder & CEO of biomanufacturing company National Resilience, Inc., where he helped raise over $2 Billion. Prior to co-founding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship Labs. Before joining Flagship, Rahul served as the Chief Operating Officer of the vaccine business unit at Takeda Pharmaceutical Co., where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. and held several positions with Merck & Co in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Directors for Codexis, and Kairos Pharmaceuticals.
Why Astatine‑211 and NK Cells Have Wall Street’s Attention
NAYA’s focus on astatine‑211 (²¹¹At) targeted alpha therapies taps into one of oncology’s most interesting frontiers: delivering highly potent radiation directly to tumor cells while limiting collateral damage to healthy tissues. Targeted alpha therapy sits alongside the now‑crowded lutetium‑177 space, positioning NAYA in what some strategists see as the “next wave” after today’s first‑generation radiotherapies.
Layer in NK cell‑engaging bifunctional antibodies—aimed at mobilizing innate immunity against tumors—and the platform reads like a checklist of what larger oncology players increasingly seek in acquisition targets: precision, combination potential, and differentiated mechanisms of action.
Radiopharma Dealmaking: From Niche to Feeding Frenzy
If radiopharma once sat in the “interesting, but niche” bucket, recent M&A has moved it firmly into the “board‑mandated strategic priority” column. Over roughly eight months, big pharma snapped up at least four of the sector’s hottest names: Novartis (NVS) acquired Mariana Oncology for around 1 billion dollars, Eli Lilly (LLY) bought Point Biopharma for about 1.4 billion dollars, AstraZeneca (AZN) purchased Fusion Pharmaceuticals for roughly 2.4 billion dollars, and Bristol Myers Squibb (BMY) acquired RayzeBio for approximately 4.1 billion dollars.
Those headline transactions sit atop a broader stack of licensing and collaboration deals, including Novartis’ multibillion‑dollar partnership with PeptiDream and Eli Lilly’s pact with Aktis Oncology that carries up to 1.1 billion dollars in potential milestones, underscoring how aggressively large players are underwriting radiopharma optionality.
Investment Wave Meets Market Expansion
The M&A surge is underpinned by market projections that would make even a jaded analyst reach for a fresh spreadsheet. One forecast pegs the radiopharmaceuticals market growing from about 9.1 billion dollars in 2023 to 26.5 billion dollars by 2031, implying a mid‑teens compound annual growth rate, while other estimates point to nearly 20 percent annual expansion, with the market potentially exceeding 40 billion dollars early in the next decade.
Consultants and strategists point to a sharp rise in clinical programs as a leading indicator: more radiopharma trials today mean more data‑driven licensing and acquisition activity tomorrow, particularly as pivotal readouts create natural “deal windows” for late‑stage assets. For investors, that translates into a sector where innovation cycles and transaction cycles are increasingly synchronized—a combination that tends to keep both bankers and biotech generalists very busy.
Where NAYA Fits in the Radiopharma Playbook
Against that backdrop, NAYA’s decision to spotlight a world‑class board looks less like a press‑release flourish and more like a strategic signal to prospective partners, acquirers, and institutional investors. Companies with targeted radiotherapeutics and immune‑engaging platforms have become prime candidates for either bolt‑on acquisitions or sizable licensing deals, particularly as incumbents race to diversify beyond lutetium‑177 into emerging isotopes like actinium‑225—and, potentially, astatine‑211.
With the radiopharma field consolidating at the top and expanding at the base, NAYA’s clinical‑stage profile and sharpened governance bench could position it as an attractive participant in the sector’s next phase, whether that means remaining independent with strategic partnerships or eventually joining the growing list of radiopharma buyouts. For now, at least, the company appears to have given itself something every ambitious oncology player wants in this market: optionality, and a board well‑equipped to use it.
The Sources
- NAYA Therapeutics – Astatine‑211 Targeted Alpha Therapies
https://www.nayatx.com/astatine-211-targeted-alpha-therapies[nayatx] - NAYA Therapeutics – Our Team / Board information
https://www.nayatx.com/copy-of-our-team-1[nayatx] - NAYA Therapeutics – Our Team (archived/old)
https://www.nayatx.com/our-team-oldd[nayatx] - Access Newswire – NAYA Therapeutics Announces World-Class Board of Directors
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-world-class-board-of-directors-1148490[accessnewswire] - Access Newswire – NAYA Therapeutics Announces European Research and Manufacturing Hub at Paris-Saclay
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-european-research-and-manufacturing-hub-at-paris-saclay-1146718[accessnewswire] - BioWorld – NAYA Therapeutics unveils GPC3-targeted Astatine‑211 radioimmunotherapy
https://www.bioworld.com/articles/721292-naya-therapeutics-unveils-gpc3-targeted-astatine-211-radioimmunotherapy[bioworld] - 1stOncology – NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline with First-in-Class GPC3-Targeted Astatine‑211 Radioimmunotherapy
https://www.1stoncology.com/blog/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-class-gpc3-targeted-astatine-211-radioimmunotherapy[1stoncology] - FirstWord Pharma – NAYA Therapeutics to Present at the Network for Optimized Astatine‑Labeled Radiopharmaceuticals
https://firstwordpharma.com/story/6515536[firstwordpharma] - Access Newswire – NAYA Therapeutics to Present at the Network for Optimized Astatine‑Labeled Radiopharmaceuticals
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-to-present-at-the-network-for-optimized-astatine-labeled-radiopharmaceuticals-noar-1147082[accessnewswire] - PharmaIndustrial India – NAYA Therapeutics Partners with Alpha Nuclide to Advance Astatine‑211 Cancer Therapies
https://www.pharmaindustrial-india.com/news/-naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-cancer-therapies[pharmaindustrial-india] - FirstWord Pharma – NAYA Announces Partnership with Alpha Nuclide to Support Astatine‑211 Radiopharmaceuticals
https://firstwordpharma.com/story/6320192[firstwordpharma] - PharmiWeb – NAYA Therapeutics Partners With IONETIX to Build a US Production Supply Network for Astatine‑211
https://www.pharmiweb.com/press-release/2025-08-21/naya-therapeutics-partners-with-ionetix-to-build-a-us-production-supply-network-for-astatine-211[pharmiweb] - FirstWord Pharma – NAYA Therapeutics Partners With IONETIX to Build a US Production Supply Network
https://firstwordpharma.com/story/5991246[firstwordpharma] - BioSpace – NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-Targeted Antibody
https://www.biospace.com/press-releases/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted-antibody-ny-303[biospace] - OncoDaily – NAYA Biosciences has Expanded the Oncology Pipeline with Novel Antibody Programs
https://oncodaily.com/insight/219228[oncodaily] - Investing.com – NAYA Biosciences expands oncology pipeline with new antibody
https://www.investing.com/news/company-news/naya-biosciences-expands-oncology-pipeline-with-new-antibody-93CH-3797583[investing] - Finance Yahoo – NAYA Therapeutics Enters into Definitive Agreements to Regain Full Rights to Key Oncology Assets
https://finance.yahoo.com/news/naya-therapeutics-enters-definitive-agreements-130000468.html[finance.yahoo] - StreetInsider – NAYA Biosciences (NAYA) nominates new Board members
https://www.streetinsider.com/Board+Changes/NAYA+Biosciences+(NAYA)+nominates+new+Board+members/24369080.html[18] - Invo Fertility – NAYA Biosciences Announces Nomination of New Board Members
https://invofertility.com/naya-biosciences-announces-nomination-of-new-board-members/[invofertility] - LinkedIn – NAYA Therapeutics Announces World-Class Board of Directors (company post)
https://www.linkedin.com/posts/naya-therapeutics_naya-therapeutics-announces-world-class-board-activity-7439683577744715776-lU_w[linkedin]
